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SUMMARY
Background
The combination of seawater baths and narrowband ultraviolet B (NB-UVB)
is a known treatment for psoriasis. This study evaluates two treatment regi-
mens that combine bathing in geothermal seawater and NB-UVB therapy in
comparison with NB-UVB monotherapy.
Methods
Sixty-eight psoriasis patients were randomly assigned to outpatient bathing in
geothermal seawater combined with NB-UVB therapy three times a week,
intensive daily treatment involving bathing in geothermal seawater combined
with NB-UVB therapy, or NB-UVB therapy alone three times a week; treat-
ment period was 6 weeks. Disease severity [Psoriasis Area Severity Index
(PASI) and Lattice System Physician’s Global Assessment scores], quality of
life (Dermatology Life Quality Index) and histological changes were evaluated
before, during and after treatment. The primary end point was the proportion
of patients who achieved PASI 75 at 6 weeks.
Results
At 6 weeks, the percentage of patients who achieved PASI 75 and PASI 90
was significantly greater for both regimens, bathing in geothermal seawater
three times a week (68.1% and 18.2%, respectively) and intensive treatment
with geothermal seawater (73.1% and 42.3%, respectively) than for NB-UVB
monotherapy (16.7% and 0%, respectively) (P < 0.05 in all comparisons).
Clinical improvement was paralleled by improvement in quality of life and
histological score and a reduction in NB-UVB doses.
Conclusion
Bathing in geothermal seawater combined with NB-UVB therapy in psoriasis
induces faster clinical and histological improvement, produces longer remis-
sion time and permits lower NB-UVB doses than UVB therapy alone.
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Water-based therapy involving natural thermal springs,
hot springs, mineral water, or seawater is currently used to
treat psoriasis patients in treatment centres all over Europe
(1). Examples of unique places for water-based therapy are
the Dead Sea in Israel, the Kangal hot spring in Turkey and
the Blue Lagoon in Iceland. Climatotherapy, such as that
received in the Dead Sea area, refers to a combination of
sun exposure and bathing in seawater where an important
role is attributed to natural UV radiation (2, 3). To simu-
late climatotherapy as linked to special geographic settings,
a combined treatment with seawater baths and artificial
UV irradation (balneophototherapy) was established. Both
open prospective studies (4–6) and randomized controlled
trials involving a large number of psoriasis patients
show the superiority of balneophototherapy over UVB
monotherapy (7, 8).
The Blue Lagoon in Iceland is a geothermal lagoon con-
taining a mixture of seawater and freshwater that formed
when warm saline fluid was discharged onto a lava field
after a geothermal power plant was built in the area in 1976
(9). Open prospective studies show that bathing in this
geothermal seawater for 3–4 weeks has beneficial effects
on psoriasis (10–13), and combination treatment with
narrowband ultraviolet B (NB-UVB) therapy further
increases the efficacy (14, 15). There are three notable dif-
ferences in psoriasis treatment at the Blue Lagoon com-
pared with the usual balneotherapy or spa therapy. The
chemical composition of the Blue Lagoon is different com-
pared with other spas, with an extremely high concentra-
tion of silica (135–140 mg/kg), moderate salinity (2.7%)
and no H2S content (Table 1) (9). To the best of our
knowledge, the dominant micro-organisms in the water,
Silicibacter lacuscaerulensis and cyanobacteria (16, 17), are
not found under similar conditions anywhere else in the
world. Due to the northerly latitude of Iceland, the natural
sun is relatively weak (18). Interestingly, no human patho-
genic bacteria or fungi have been shown to thrive in the
lagoon (19).
No randomized controlled trials have been conducted to
assess the efficacy of bathing in geothermal seawater com-
bined with NB-UVB therapy compared with traditional
NB-UVB therapy. In addition, the histopathological and
psychosocial effects of geothermal seawater baths com-
bined with NB-UVB therapy have never been evaluated
before. Here we present the results of a randomized con-
trolled study evaluating the clinical, histopathological and
psychosocial efficacy of NB-UVB therapy alone and two
different treatment regimens including geothermal seawa-
ter baths followed by NB-UVB therapy.
MATERIALS AND METHODS
Study design and patients
This study was a randomized open multi-arm parallel
study to evaluate NB-UVB therapy and two treatment regi-
mens including bathing in geothermal seawater combined
with NB-UVB therapy in patients with chronic plaque pso-
riasis. The Icelandic National Bioethics Committee (08-
097-S1) and the Icelandic Data Protection Authority
approved the study protocol. Patients provided written
consent to participate in the study. Eligible patients were
recruited to the study from September 2009 to May 2010
and followed up for 2 years. One hundred and nineteen
patients were screened. The majority of the patients (80%)
were referred by a dermatologist, but some responded to
an advertisement in a newspaper. The diagnosis of psoria-
sis had been confirmed by a dermatologist in all cases. Key
inclusion criteria were the following: (a) diagnosis of
chronic plaque psoriasis; (b) Psoriasis Area and Severity
Index (PASI) score (20) of 7 or higher; and (c) being unre-
sponsive to topical treatment and being a candidate for
phototherapy or systemic treatment. Patients with other
forms of psoriasis (e.g. guttate, pustular or erythrodermic)
or skin diseases that could interfere with study evaluations
were excluded. All ongoing psoriasis treatment was
stopped at least 4 weeks prior to inclusion in the study.
Of the 119 patients screened, 68 patients fulfilled all
criteria and were enrolled in the study. All patients pro-
vided informed consent before participating in the study.
Of the 51 excluded patients, 27 had a PASI score lower
than 7, and 6 had another psoriasis subtype. Ten patients
were excluded because of ongoing active treatment for
psoriasis or psoriatic arthritis. Data were collected at the
Department of Dermatology at the Landspitali University
Table 1. Characteristics of the water in the Blue
Lagoon
pH 7.70
Temperature (°C) 24
Dissolved solids (mg/kg water)
SiO2 137
Na+ 9280
K+ 1560
Ca2+ 1450
Mg2+ 1.41
CO2 16.5
SO42- 38.6
H2S 0.0
Cl- 18 500
F- 0.14
Total 31 900
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Hospital in Reykjavik and the Blue Lagoon Clinic. Blood
and histological samples were processed and analysed at
the Departments of Immunology and Pathology at the
Landspitali University Hospital.
Treatment regimens
For randomisation of the patients, a random number table
was used. Patients were randomly assigned, in a 1:1:1 ratio,
to three therapeutic arms:
1 Outpatient bathing in geothermal seawater and
NB-UVB treatment (GSW). The treatment included
bathing in geothermal seawater for 1 h and NB-UVB
therapy immediately afterwards three times a week for 6
weeks. Patients were advised to rub the silica mud from the
lagoon on the skin while bathing and to use moisturizing
cream (Blue Lagoon Mineral Intensive Cream), which
contains mineral salts from the lagoon and no active ingre-
dients, twice daily.
2 Intensive treatment in geothermal seawater and
NB-UVB therapy (IT-GSW). This treatment protocol con-
sisted of bathing in geothermal seawater for 1 h two times
a day and NB-UVB therapy once daily immediately after
the first bath six times/week for 2 weeks. Patients were
advised to rub the silica mud from the lagoon on the skin
while bathing and to use moisturizing creams twice daily
(Blue Lagoon Mineral Intensive Cream). After 2 weeks,
patients were treated with a conventional outpatient
NB-UVB therapy three times a week for 4 weeks.
3 Conventional narrowband UVB therapy (NB-UVB).
This group received a regular, monitored NB-UVB radia-
tion therapy three times weekly for 6 weeks. Patients took
a shower immediately before the UVB treatment was given
and used moisturizing creams containing no active ingre-
dients twice daily (Eucerin Original Healing lotion,
Beiersdorf, Hamburg, Germany).
The same NB-UVB treatment protocol was used for
all patients based on skin type, with initial doses of 130–
400 mJ/cm2 with subsequent increases of 15–65 mJ/cm2
after each treatment session. The UVB source was
a Waldmann 7001 cabin (Waldmann, Villingen-
Schwenningen, Germany) with an NB-UVB lamp (TL01,
Philips, Eindhoven, the Netherlands) with peak emission
at 311 nm.
Efficacy end points
The primary objective of the study was to assess the
efficacy of three different psoriasis regimens: conventional
NB-UVB therapy and two different combination treat-
ments involving bathing in geothermal seawater. The
primary efficacy variable was the proportion of patients
who achieved a reduction in PASI score (20) of at least
75% (PASI 75) after 6 weeks of treatment. Key secondary
efficacy end points included (a) the proportion of patients
with a reduction in PASI score of at least 90% (PASI 90) at
week 6; (b) the proportion of patients with a Lattice System
Physician’s Global Assessment score (Lattice score) (21) of
‘clear of disease’ or ‘almost clear’ at week 6; (c) the change
from baseline in Dermatology Life Quality Index (DLQI)
(22) at week 10; (d) histological changes from baseline in
skin biopsies at week 6; and e) the number of days with
clearance or marked improvement of the disease (time to
relapse).
The DLQI is a 10-item questionnaire that determines
whether psoriasis affects patient-reported quality of life,
with overall scores ranging from 0 (not at all) to 30 (very
much) (22), and it was assessed at baseline and at 10weeks.
Trozak’s histologic grading system for psoriasis (23) was
used for histological blinded assessment of the skin biop-
sies, as it is a more observer-independent assessment tool.
The presence of predetermined histopathological charac-
teristics of psoriasis (regular elongation of rete ridges,
club-shaped rete ridges, oedema and elongation of dermal
papillae, perivascular infiltrate in the upper dermis, absent
granular layer, parakeratosis, suprabasal mitosis, Munro’s
microabscesses and spongiform pustules) was scored in
routine sections of biopsies. The individual parameters
were scored from 1 to 3, and a cumulative score (0–19) was
recorded for each biopsy specimen.
Disease activity was assessed at baseline and 1, 2, 4, 6 and
10 weeks after beginning the treatment. All patients were
examined in the following order by the same physician
(JHE): clinical examination, photographic documentation,
PASI score determination, Lattice score determination and
quality-of-life assessment with the DLQI. In addition, after
these assessments at baseline, week 2 and week 6, a 4-mm
punch biopsy from a target lesion was obtained from seven
patients in each treatment group. The thickest lesion on the
extremities was selected as the target lesion.
Patients who did not achieve at least a 50% reduction
from baseline in PASI score at week 6 were either with-
drawn from the study (non-responders) or invited to cross
over to receive intensive combination treatment. Patients
in all study groups who achieved a 50–75% reduction in
PASI score continued NB-UVB therapy three times a week
for 4 weeks or until attainment of PASI 75/PASI 90, and
patients who achieved PASI 75 were invited to continue
NB-UVB therapy until attainment of PASI 90 (maximum
10 weeks/patient).
Finally, to evaluate how long the effect of each treatment
lasted, the number of days until relapse was calculated.
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Patients were followed up for 1 year with telephone inter-
views where they were asked if they had received
retreatment with other antipsoriatic therapies (topical
treatment, phototherapy or systemic therapy). We defined
the number of days to relapse as the number of days from
the study treatment until retreatment.
Statistical analysis
The sample size calculation was based on the primary end
point of PASI 75 after 6 weeks of treatment. The study was
sufficiently powered to detect a difference of 20% between
the combination treatment groups and the UVB group.
Given these assumptions and taking into account the
results of prior studies (10–15), a sample size of 15 patients
per treatment group provided more than 99% power to
detect at least one pairwise treatment effect in the primary
end point at an overall 5% level of significance.
Efficacy data from all randomised patients were ana-
lysed on an intention-to-treat basis. Patients who discon-
tinued study treatment due to unsatisfactory therapeutic
effect or who did not follow the study treatment protocol
were regarded as treatment failures. For analysis in such
cases, missing values were replaced with the most recently
available values for all efficacy variables (last observation
carried forward) (24). Patients who did not achieve more
than a 50% reduction in PASI score and crossed over to
receive IT-GSW were included in efficacy summaries for
IT-GSW (Fig. 1). The proportions of patients responding
to treatment were compared using the two-sided Fisher’s
exact test. Continuous response variables were compared
with the use of analysis of variance (ANOVA). Also, we
used Spearman’s correlation coefficient to show the cor-
relation between different parameters, including all visits.
All statistical tests were two-sided and performed at an
alpha level of 0.05.
119 screened
68 randomised
Bathing in GSW+UVB (GSW) three 
times/week for 6 weeks
(n = 22)
UVB therapy (UVB) three 
times/week for 6 weeks             
(n = 24)
Intensive treatment (IT-GSW) for 2 
weeks followed by NB-UVB therapy 
for 4 weeks
(n = 22)
Discontinued (n = 6):
- 2 non-responders 
(9.1%)
- 4 protocol 
violators (18.2%)
Discontinued (n = 5):
- 3 protocol 
violators (13.6%)
- 1 adverse 
reaction (4.5%)
- 1 personal
Discontinued (n = 5):
- 3 non-
responders 
(12.5%)
- 2 protocol 
violators (8.3%)
16 completed study through 
week 10
21 completed study through 
week 10
19 completed study through 
week 10
6 continued 
NB-UVB 
therapy
through week 
10
6 continued 
NB-UVB 
therapy
through week 
10
16 continued 
NB-UVB 
therapy
through week 
10
W
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K
S
0
4
6
8
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2
2 non-
responders 
crossed over 
to IT-GSW
2 non-
responders 
crossed over 
to IT-GSW
Fig. 1. Disposition of patients and reasons for discontinuation. Sixty-eight psoriasis patients enrolled in the study, but 16 patients
discontinued: 5 because of lack of efficacy (Psoriasis Area Severity Index score still below 50 after 6 weeks of treatment), 1
because of an adverse event, 9 because of protocol violation (missing treatment) and 1 because of personal reasons. Two
non-responders in the UVB group and 2 non-responders in the GSW group crossed over to the IT-GSW group. GSW, geothermal
seawater.
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RESULTS
Patients
All treatment groups were well balanced with respect to
demographic characteristics (Table 2). The mean baseline
PASI score was 12.3 ± 5.2 in the GSW group, 11.6 ± 6.2 in
the IT-GSW group and 11.1 ± 4.9 in the UVB therapy
group (P = 0.22). Of 68 patients, 56 completed the study
(82.4%; Fig 1). Five patients were withdrawn as they did
not achieve a 50% reduction in PASI score after 6 weeks of
treatment (non-responders). Four of them were assigned
to the IT-GSW group. One patient entered the cross-over
IT-GSW group a few days after withdrawal, two patients 2
weeks after withdrawal and one patient more than 4 weeks
after withdrawal. Other reasons for early termination
included adverse events (1/68; 1.5%), protocol violations
(9/68; 13.2%) and personal reasons (1/68; 1.5%).
Clinical efficacy
After 6 weeks of treatment, 20/26 patients (77.0%) of the
patients in the IT-GSW group and 15/22 (68.2%) in the
GSW group met the primary end point of a 75% reduction
in PASI score, compared with only 4/24 (16.7%) patients
treated with NB-UVB therapy alone (P < 0.001 for GSW
and IT-GSW vs. NB-UVB) (Table 3, Fig. 2a and Fig. 2b).
In addition, 11 out of 26 patients (42%) in the IT-GSW
group and 4 out of 22 patients (18%) in the GSW group
showed a 90% reduction in PASI score compared with no
patients in the UVB group (0%; P < 0.05 for both com-
parisons; Table 3 and Fig. 2d).
According to the protocol, all the patients who achieved
PASI 90 at week 6 discontinued active treatment, and
patients who achieved PASI 75 were invited to continue
NB-UVB therapy until attainment of PASI 90 (maximum
10 weeks/patient). Respectively, 6/26 (30.8%) of the
patients in the IT-GSW group, 6/22 (31.8%) in the GSW
group and 16/24 (66.8%) in the UVB group continued
NB-UVB therapy three times a week until week 10 or until
attainment of PASI 75/PASI 90 (Fig. 1). The time required
for attaining a 75% reduction in PASI score was signifi-
cantly shorter for both the IT-GSW group (29.1 ± 25.2
days) and the GSW group (35.5 ± 10.4 days) compared
with the UVB group (62.3 ± 14.0 days) (P < 0.001 for both
comparisons; Fig. 2b and Fig. 2c). No statistical difference
was found between the combination treatment groups
(P > 0.05). The number of NB-UVB sessions required for
the patient to attain PASI 75 was also significantly less
Table 2. Baseline patient characteristics
Characteristics GSW (n = 22) IT-GSW (n = 24) UVB (n = 24) P value†
Age (years), mean ± SD 41 ± 10.8 42.2 ± 16 37.9 ± 14.4 0.37
Male, n (%) 12 (55) 12 (50) 15 (63) 0.82
Body mass index (kg/m2), mean ± SD 28 ± 5 28.6 ± 5.4) 28.8 ± 7.1 0.96
Duration of psoriasis (years), mean ± SD 20 ± 14 16.4 ± 11 12.3 ± 8.1 0.09
Psoriatic arthritis, n (%) 4 (19) 3 (13) 5 (20) 0.71
Nail psoriasis, n (%) 10 (43) 12 (50) 9 (38) 0.61
PASI score, mean ± SD‡ 12.3 ± 5.2 11.6 ± 6.2 11.1 ± 4.9 0.22
Lattice score§ Moderate to severe Moderate to severe Moderate to severe 1.00
DLQI score, mean ± SD¶ 7 ± 4.2 11.6 ± 6.2 7.3 ± 5.1 0.017*
Treated previously, n (%)
Blue Lagoon 6 (27) 10 (42) 7 (29) 0.57
Topical agent 21 (95) 23 (100) 21 (88) 1.00
Phototherapy 21 (95) 19 (79) 16 (67) 0.51
Systemic therapy 2 (1) 2 (8) 1 (4) 0.61
Smoking, n (%) 6 (27) 8 (33) 4 (17) 0.77
Family history, n (%) 18 (82) 12 (50) 14 (58) 0.35
*P < 0.05.
†For comparisons across all treatment groups; calculated by means of ANOVA for continuous variables and χ2-test for
categorical variables. ‡Possible scores range from 0 to 72, with higher scores indicating more severe disease.
§Possible scores range from ‘clear of disease’ to ‘severe disease’.
¶Possible scores range from 0 to 30, with higher scores indicating worse health-related quality of life.
GSW, bathing in geothermal seawater combined with UVB treatment; IT-GSW, intensive treatment in geothermal
seawater combined with UVB treatment; UVB, UVB treatment alone; PASI, Psoriasis Area Severity Index; Lattice, Lattice
System Physician’s Global Assessment; DLQI, Dermatology Life Quality Index.
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(GSW 14.7 ± 4.2, IT-GSW 17.2 ± 10.0, UVB 25.0 ± 6.6;
P = 0.001 for GSW and IT-GSW vs. UVB; Table 3).
Furthermore, the mean NB-UVB dose for achieving PASI
75 was 5.8 ± 2.6 J/cm2 for the GSW group and 8.3 ± 5.9 J/
cm2 for the IT-GSW group compared with 18.58 ± 8.25 J/
cm2 for the UVB group (P < 0.001 for GSW and IT-GSW
vs. UVB; Table 3).
When the Lattice score was examined, higher percent-
ages of patients who received combination treatment
(GSW and IT-GSW) had a Lattice score of ‘clear of disease’
or ‘almost clear’ compared with patients treated with
NB-UVB therapy alone (P < 0.01 for GSW and P < 0.001
for IT-GSW vs. UVB) (Table 3; Fig 2c). No statistical
difference was found between GSW and IT-GSW
(P > 0.05) except in the percentages of patients with
a 90% improvement in the PASI score at week 6 and in the
PASI score results (P < 0.05). These clinical findings were
also reflected by a significant correlation between the
PASI score and Lattice score (Spearman’s r = 0.7318,
P < 0.0001).
Patients who received combined treatment showed
better response in areas poorly exposed to NB-UVB radia-
tion compared with patients treated with NB-UVB therapy
alone. This was observed in 10 patients in the GSW group,
13 patients in the IT-GSW group and 12 patients in the
UVB group, and these areas were noted to have cleared in
7 patients in the GSW group compared with only 2
patients treated with UVB alone.
Despite the large difference in number of days until
relapse of psoriasis between patients in the GSW group and
those in the UVB group (246.1 ± 161.0 vs. 140.9 ± 165.3;
P = 0.0796), the difference did not reach statistical signifi-
cance. However, the difference in number of days was
statistically significant (283.9 ± 137.0 vs. 140.9 ± 165.3;
P < 0.0083) in favour of the IT-GSW treatment group
when this treatment was compared with NB-UVB therapy
alone. Nine out of 19 patients (47.4%) who received
NB-UVB therapy alone had started another treatment only
1 month after the last treatment session, compared with
only one (1/21; 4.8%) of the patients in the IT-GSW group
(P = 0.0028) and 3 out of 16 patients (18.8%) in the GSW
group (P = 0.15).
Quality of life
Twelve patients out of 26 (46%) in the IT-GSW group and
9 patients of 22 (40%) in the GSW group achieved a DLQI
score of 0 or 1 by week 10 compared with 3 patients out of
24 (12%) who were treated with NB-UVB therapy alone
(P < 0.05 for both comparisons; Table 3).
Histological response to treatment
At baseline, typical histopathological characteristics of
psoriasis were seen in all patients (hyperkeratosis, elon-
gated rete ridges, perivascular mononuclear cell infiltrate
Table 3. Response to treatment
GSW (n = 22) IT-GSW (n = 26) UVB (n = 24)
PASI 75, n (%)
6 weeks 15 (68.1)*** 20 (77.0)*** 4 (17.0)
10 weeks 13 (59.0) 17 (65.4) 13 (54.2)
PASI 90, n (%)
6 weeks 4 (18.2)* 11 (42)*** 0 (0)
10 weeks 4 (18.2) 6 (23.1) 2 (8.3)
Lattice score of ‘clear’/‘almost clear’, n (%)
6 weeks 14 (63.6)** 17 (65)*** 4 (17)
10 weeks 12 (55)* 15 (58)* 4 (17)
DLQI score 0 or 1 at 10 weeks, n (%) 9 (40.9)* 12 (46.2)* 3 (12.5)
Treatment intensity needed to attain PASI 75, mean ± SD
UVB treatment sessions (n) 14.7 ± 4.2*** 17.9 ± 10.0** 25.0 ± 6.6
Total UVB dose (J/cm2) 5.8 ± 2.6*** 8.3 ± 5.9*** 18.6 ± 8.3
Length of treatment (days) 35.5 ± 10.4*** 29.1 ± 25.2*** 62.3 ± 14.0
*P < 0.05.
**P < 0.01.
***P < 0.001.
GSW, bathing in geothermal seawater combined with UVB treatment; IT-GSW, intensive treatment in geothermal
seawater combined with UVB treatment; UVB, UVB treatment alone; PASI, Psoriasis Area Severity Index; Lattice, Lattice
System Physician’s Global Assessment; DLQI, Dermatology Life Quality Index.
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and Munro abscesses; see Fig 3). Patients in both combi-
nation treatment groups showed a significant decrease in
psoriatic histological symptoms as measured by the Trozak
score after only 2 weeks of treatment: from 10.5 ± 4.7 to
3.29 ± 3.7 (P < 0.05) for the GSW group and from
8.1 ± 2.4 to 3.0 ± 2.4 (P < 0.05) for the IT-GSW group
(Fig 3). The histological symptoms were further reduced in
biopsies from patients in the IT-GSW group after 6 weeks
of treatment, to 0.5 ± 1.0 (P < 0.01, Fig 3). There was no
significant difference in Trozak score in the GSW group
between 2 and 6 weeks (Fig 3). No significant decrease was
observed for patients treated with UVB therapy alone
(10.0 ± 2.6 before treatment, 7.7 ± 1.6 after 2 weeks and
4.0 ± 3.7 after 6 weeks of treatment). In addition, no sig-
nificant difference was observed when all the treatment
groups were compared with each other. Trozak histologi-
cal score was significantly correlated with both PASI score
(Spearman’s r = 0.42, P < 0.001) and Lattice score (Spear-
man’s r = 0.55, P < 0.0001).
Safety
One treatment-related adverse event was reported, where
one patient in the IT-GSW group developed an itchy
papular eruption confined to the forearm, which was diag-
nosed as polymorphous light eruption. The patient was
treated with topical steroids and excluded from the study.
Two patients reported upper respiratory tract infections,
one in the GSW group and one in the IT-GSW group. The
most commonly reported adverse event was erythema at
the biopsy site, which occurred in 4 (18%) patients in the
GSW group, 5 (21%) in the IT-GSW group and 4 (17%) in
Fig. 2. Intention-to-treat analysis: proportion of patients achieving clinical responses from baseline through week 6 using
intention-to treat population. (a) Median percentage reduction of baseline Psoriasis Area Severity Index (PASI) score through
week 6. (b) Percentage of patients attaining 75% reduction from baseline PASI score. (c) Percentage of patients attaining Lattice
System Physician’s Global Assessment score of ‘clear’ or ‘almost clear’ (0 or 1). (d) Percentage of patients attaining 90% reduction
from baseline PASI score. Last observation carried forward to week 6 for dropouts. GSW, outpatient bathing in geothermal
seawater combined with UVB treatment; IT-GSW, intensive bathing in geothermal seawater combined with UVB treatment; UVB,
UVB monotherapy. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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the UVB therapy group. No serious adverse events were
reported during the study period.
DISCUSSION
This study confirms previous reports (10–15) that the
addition of UVB therapy to bathing in geothermal seawa-
ter is an effective treatment for psoriasis. NB-UVB therapy
combined with bathing in geothermal seawater, compared
with NB-UVB therapy alone, was associated with faster
reduction in PASI score, Lattice score and Trozak histo-
logical score, as well as quality-of-life (DLQI) score. In
addition, the combination treatments resulted in reduced
total NB-UVB dose and a longer remission.
The combination of bathing in geothermal seawater and
NB-UVB therapy had a rapid onset of action, as evidenced
by significant reductions in PASI score occurring as early
as week 1 and by the significantly higher percentage of
patients achieving PASI 75 or Lattice score of ‘clear’ or
‘almost clear’ as early as week 1. Furthermore, 42% of
patients who received intensive combination treatment
achieved PASI 90 after only 6 weeks of treatment.
After 6 weeks, only 17% of the NB-UVB-treated patients
had reached PASI 75. Therefore, most of these patients
continued NB-UVB therapy until week 10. However, most
of the patients in the combination treatment groups had
reached PASI 75 or PASI 90 after 6weeks and discontinued
treatment. The mean total cumulative dose of NB-UVB,
Fig. 3. Histological assessment using Trozak’s grading system before and after 2 and 6 weeks of treatment. (a) Patients who
underwent outpatient bathing in geothermal water combined with UVB therapy (GSW). (b) Patients who underwent inpatient
bathing in geothermal water combined with UVB therapy (IT-GSW). (c) Patients who underwent UVB therapy alone (UVB). (d–f)
Representative photographs from one patient each in the GSW group (d), IT-GSW group (e) and UVB group (f). *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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the number of exposures and the time required to achieve
at least PASI 75 were significantly lower in both combina-
tion treatment groups compared with the UVB therapy
group (P < 0.001).
The clinical improvement was paralleled by improve-
ment in quality of life (DLQI score) and Trozak histo-
logical score. The blinded histopathological evaluation
shows that combination treatment with bathing in geo-
thermal seawater and NB-UVB therapy almost com-
pletely eliminated the characteristics of psoriasis as
measured by Trozak score after only 2 weeks of treat-
ment. The fact that the PASI evaluation was not blinded
is a limitation of the study. However, the histological
assessment was blinded, and it demonstrated a significant
correlation with the clinical findings. The DLQI assess-
ment was carried out at baseline and at week 10. The
10th-week evaluation point might not be optimal, but it
was considered that too-frequent evaluation could lead
to bias in the DLQI score.
After 6 months, only 30% of patients in either
combination treatment group had relapsed (started
another therapy), compared with 56% of patients treated
with UVB monotherapy. The scalp and intertriginous
areas are poorly exposed during NB-UVB therapy, and
this could possibly explain why efficacy was lower in the
UVB monotherapy group. It has been shown that the
silica mud and the micro-organisms growing in the geo-
thermal seawater are bioactive and can improve the skin
barrier of normal skin and prevent premature skin aging
(25). It is therefore possible that ‘active ingredients’
in the geothermal seawater have a healing effect on
psoriasis.
Bathing in tap water or hot baths may have a beneficial
effect on psoriasis, but to our knowledge, no clinical
studies have shown this. One randomized controlled trial
(8) demonstrates that bathing in tap water before UVB
exposure is slightly better than UVB monotherapy. In the
present study, the patients who were treated with UVB
therapy alone took a shower immediately before the UVB
treatment was given to make the treatment groups as com-
parable as possible. In addition, it is well documented
that hot seawater baths alone have a minor therapeutic
effect, usually not exceeding a 30% improvement in PASI
score (5, 26).
We do not yet fully understand the biological basis for
the efficacy of the geothermal seawater psoriasis treat-
ment. At present, there are several ongoing studies trying
to identify and isolate the agents responsible for the ben-
eficial effects of bathing in geothermal seawater.
Treatment options for psoriasis have expanded consid-
erably in recent years. Many new therapeutic agents, such
as the biologic drugs, are expensive and can cause serious
side effects. Despite the absence of long-term major thera-
peutic efficacy, UV radiation therapy combined with
balneotherapy remains an inexpensive and clinically ben-
eficial therapeutic option for psoriasis patients.
In conclusion, patients bathing in geothermal seawater
before NB-UVB treatment need fewer sessions and lower
cumulative doses compared with patients treated with
NB-UVB monotherapy. In addition, combination treat-
ment induces faster improvement in clinical and histologi-
cal scores and a longer remission time after treatment as
compared with NB-UVB therapy alone.
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